ASCO Breast Cancer
Latest News
Beyond Weight Loss, Limited Bariatric Surgery Benefits in Older Adults
“The findings from this study suggest a limited role of bariatric surgery in older patients for the prevention of obesity-related cancer or...
Conference Coverage
Outcomes with CDK4/6 Inhibitors Vary in BC
A large Italian study found real-world differences in short-term outcomes among first line CDK4/6 inhibitors palbociclib, ribociclib and...
Latest News
What Does Hormone Receptor Mean in BRCA-Associated BC?
Large international study highlights the impact of hormone receptor status in young women with BRCA-associated breast cancer.
Latest News
Black Women With Breast Cancer Face Clinical Inequities
Retrospective analysis finds no clinical trial enrollment, reduced use of targeted treatment, and shortened survival.
Latest News
Circulating Tumor DNA Hints at BC Recurrence Risk
Despite suggestive results, researchers say it’s too early to use ctDNA for adjuvant decisions in early, high-risk breast cancer.
Conference Coverage
Cognitive Decline Minimal After Endocrine + CDK4/6 Inhibition in BC
Authors investigate cognitive functioning in the same cohort used in the SONIA trial and a matched control group of individuals that did not have...
Conference Coverage
Eribulin Similar to Taxane When Paired With Dual HER2 Blockade in BC
Patients with HER2-positive, locally advanced or metastatic breast cancer who cannot tolerate the standard taxane-based regimen have a new option...
Conference Coverage
PFS Benefits Seen With Palbociclib + Endocrine Therapy in Breast Cancer
Palbociclib plus endocrine therapy or chemotherapy: Which is best in HR+/HER2- metastatic breast cancer?
Feature
New ADC results mixed in metastatic breast cancer
While T-DXd showed promise for yet another indication at ASCO, other findings underscored that much still remains to be learned about this drug...
Conference Coverage
Adjuvant Avelumab Benefits Seen in High Risk, Triple Negative BC
Researchers conduct first randomized phase 3 trial of patients with TNBC treated with adjuvant avelumab.
Conference Coverage
Platinum Add-On Improves Survival in Early TNBC
Trial outcomes provide strong evidence for incorporating carboplatin into both the neoadjuvant and adjuvant settings in patients with early-stage...